Country: Malta
Language: English
Source: Medicines Authority
PETHIDINE HYDROCHLORIDE
Mercury Pharmaceuticals (Ireland) Limited 4045 Kingswood Road, City West Business Park, Co, Dublin, Ireland
N02AB02
PETHIDINE HYDROCHLORIDE 50 mg/ml
SOLUTION FOR INJECTION
PETHIDINE HYDROCHLORIDE 50 mg/ml
POM
ANALGESICS
Licence number in the source country: NOT APPLICAPABLE
Authorised
2007-04-16
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PETHIDINE HYDROCHLORIDE 50MG/ML SOLUTION FOR INJECTION READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Pethidine Hydrochloride 50mg/ml Solution for Injection but will be referred to as “Pethidine Injection” throughout the remainder of this leaflet. WHAT IS IN THIS LEAFLET 1. What Pethidine Injection is and what it is used for 2. What you need to know before you are given Pethidine Injection 3. How Pethidine Injection is given to you 4. Possible side effects 5. How to store Pethidine Injection 6. Contents of the pack and other information 1. WHAT PETHIDINE INJECTION IS AND WHAT IT IS USED FOR Pethidine Injection is a type of medicine called an opioid analgesic. The word opioid means a substance similar to opium, for instance strong pain relievers such as morphine or codeine. An analgesic is a medicine that can be used to relieve pain. Pethidine Injection is used to relieve moderate to severe pain, including pain associated with childbirth, before an operation and as a medicine given before administration of an anaesthetic. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN PETHIDINE INJECTION YOU SHOULD NOT BE GIVEN PETHIDINE INJECTION • if you are allergic to pethidine hydrochloride or any of the other ingredients in this medicine (listed in section 6) • if you have any problems that affect your breathing including chronic bronchitis or asthma, shallow breathing or other breathing difficulties • if you are taking monoamine oxidase inhibitors (MAOIs) or have been taking them within the last two weeks. MAOIs (e.g. phenelzine, moclobemide, isocarboxazid selegiline and rasagiline) are medicines used to Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Pethidine Hydrochloride 50mg/ml Solution for Injection (2ml) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1ml of solution contains 50mg of Pethidine Hydrochloride. Each 2ml of solution contains 100mg of Pethidine Hydrochloride. Excipient with known effect None For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (Injection) A clear colourless, sterile solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As an analgesic in the relief of moderate to severe pain. As an adjunct in anaesthesia. For preoperative medication During labour 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ The usual dose is 25 to 100mg intramuscularly or subcutaneously or 25 to 50mg by slow intravenous injection. Dosage may be repeated if required every 4 hours. _Elderly or debilitated patients _ In view of their greater sensitivity, the initial dose should not exceed 25mg. _Paediatric_ _population_ The usual dose is 0.5 to 2mg/kg body weight. Dosage may be repeated if required every 4 hours. The use of a small graduated syringe is recommended for the accurate administration of dosages given to children. In the absence of graduated syringes, the solution should be diluted with Water for Injections before measuring the dose. Method of administration Pethidine Hydrochloride 50mg/ml Solution for Injection is for administration by subcutaneous, intramuscular or slow intravenous injection. 4.3 CONTRAINDICATIONS • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Use of pethidine should be avoided in patients with diabetic acidosis where there is danger of coma • In comatose patients • Use of pethidine in patients with Phaeochromocytoma may result in hypertensive crisis. • Use in patients who are receiving, or have within two weeks received, monoamine oxidase inhibitors (including moclobemide, and the monoamine B inhibitors selegiline and rasagili Read the complete document